LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading ...

Please provide your email address to receive an email when new articles are posted on . The integration of second-generation anti-vascular endothelial growth factor (VEGF) therapies into treatment ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Vor Biopharma Inc. (VOR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy ...

Today, the durable medical equipment management (DME) process can be fragmented, inefficient, and unreliable - leading to errors and delays that impact member health, inflate costs for health plans, ...

Vor Biopharma (NASDAQ:VOR) has been upgraded to Buy from Hold at Stifel as confidence in the company’s long-term potential has grown following prospects for its lead asset, telitacicept. The shares of ...

Durable medical equipment (DME) such as CPAP machines and hospital beds helps keep many patients out of expensive nursing home care and in their own homes. Unfortunately, creating the right payment ...

On Wednesday, Vor Bio Inc. (NASDAQ:VOR) announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in ...

The recombinant fusion protein drug telitacicept from Remegen Co. Ltd. and Vor Bio Inc. has notched a phase III win in treating adults with IgA nephropathy. The clinical trial of the fusion protein ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.